Switzerland-based Novartis, United States-based Amgen and Banner Alzheimer's Institute have decided to stop the clinical programme with BACE1 inhibitor, CNP520 (umibecestat), for the prevention of Alzheimer's disease, it was reported on Friday.
The collaboration will discontinue the assessment of CNP520 in two pivotal phase II/III studies in the Alzheimer's Prevention Initiative Generation Programme. Novartis said that an evaluation of un-blinded data during a regular pre-planned review identified worsening in some measures of cognitive function. The sponsors therefore concluded that the potential benefits for the study's participants did not outweigh the risks.
CNP520 was being assessed for safety and efficacy in the prevention or delay of the onset of Alzheimer's in people at high risk for developing symptoms based on their age and genetic status.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval